Celgene Corp
Article Abstract:
The Food and Drug Administration granted fast track status to Celgene Corp.'s anticancer compound while GlaxoSmithKline granted the company promotion rights to another anticancer agent. Research and development expenses will increase but a small profit is expected in 2003 and 2004.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Biotechnology Industry
Article Abstract:
Stocks in the biotechnology industries lost some ground in the market and the effects of President George Bush's policies and Medicare reform legislation's e ffects on the industry are discussed .
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Techne Corp
Article Abstract:
Techne Corp.'s market for its products has weakened and its share price dropped by Wall Street, but equity still offers 3 - 5 year capital gains potential.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: